Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959929 · ClinicalTrials.gov registry record · NA
Wearable Focal Vibration for Chemotherapy-Induced Peripheral Neuropathy
A NA study of Chemotherapy-induced Peripheral Neuropathy, sponsored by University of Oklahoma.
- Active
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04959929: Active NA study of Chemotherapy-induced Peripheral Neuropathy, sponsored by University of Oklahoma.
NCT04959929 is a NA study of Chemotherapy-induced Peripheral Neuropathy that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 15 participants, below the 138-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04959929, a NA study of Chemotherapy-induced Peripheral Neuropathy, is active but no longer recruiting, sponsored by University of Oklahoma.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will perform an early Phase I feasibility study with single-arm, double-baseline repeated measured design. The investigators will test the feasibility of using focal vibration to improve symptoms of persistent CIPN.
Primary Outcome
Percent of interested individuals who enrolled.
Conditions Studied
Interventions
- DEVICE Focal vibration therapy
Study Locations (1)
Oklahoma
- Stephenson Cancer Center, OU Health - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-02-09 |
| Est. Completion | 2025-07-01 |
| Phase | NA |
What the registry record for NCT04959929 still lists
NCT04959929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 138-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Focal vibration therapy is the first listed.
NCT04959929 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT04959929 about?
NCT04959929 is a clinical study titled "Wearable Focal Vibration for Chemotherapy-Induced Peripheral Neuropathy". This study will perform an early Phase I feasibility study with single-arm, double-baseline repeated measured design. The investigators will test the feasibility of using focal vibration to improve symptoms of persistent CIPN.
What is the current status of trial NCT04959929?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2023-02-09. Estimated completion is 2025-07-01.
What conditions does trial NCT04959929 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.
What interventions are being tested in trial NCT04959929?
The interventions under investigation include: Focal vibration therapy (DEVICE).
Who is sponsoring clinical trial NCT04959929?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04959929 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04959929's enrollment target sits among peer trials
15 27th of 29 higher than 3 of 29 other Chemotherapy-induced Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryocompression for CIPN
RECRUITING · NA
-
VGAIT for Chemotherapy-induced Peripheral Neuropathy
RECRUITING · NA
-
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
RECRUITING · NA
-
Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · NA
-
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · NA
-
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI